# Amikacin Penetration Into the Cerebrospinal Fluid

> **NCT00362245** · PHASE4 · WITHDRAWN · sponsor: **Rambam Health Care Campus**

## Conditions studied

- Gram Negative Meningitis
- Post Traumatic Bacterial Meningitis

## Interventions

- **DRUG:** Systemic and Intra-Thecal Amikacin Therapy

## Key facts

- **NCT ID:** NCT00362245
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-09
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of participants
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362245, "Amikacin Penetration Into the Cerebrospinal Fluid". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00362245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*